Tauroursodeoxycholic Acid for Treatment of Primary Biliary Cirrhosis: A Dose-Response Study

Digestive Diseases and Sciences

Volumn 41, Issue 4, 1996, Pages 809-815

  Crosignani, Andrea ^a   Battezzati, Pier Maria ^b   Setchell, Kenneth D R ^b   Invernizzi, Pietro ^b   Covini, Giovanni ^b   Zuin, Massimo ^b   Podda, Mauro ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

Bile acids; Chronic cholestasis; Primary biliary cirrhosis; Tauroursodeoxycholic acid

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; TAUROURSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; HUMAN; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BILE; CHOLESTEROL; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME TESTS; HUMANS; ISOMERISM; LIVER; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; TAUROCHENODEOXYCHOLIC ACID; TIME FACTORS;

EID: 0029922431     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02213140     Document Type: Article

References (46)

1. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR: Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: In vitro studies in rat hepatocytes and human erythrocytes. Hepatology 14:920-426, 1991
2. Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, Vlahcevic ZR: Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 100:203-211, 1991
3. Nakai T, Katagiri K, Hoshino N, Hayakawa T, Ohiwa T: Microtubule-independent choleresis and anti-cholestatic action of tauroursodeoxycholate in colchicine treated rat liver. Biochem J 288:613-617, 1992
4. Tsukahara K, Kanai S, Ohta M, Kitani K: Taurine conjugate of ursodeoxycholate plays a major role in the hepatoprotective effect against cholestasis induced by taurochenodeoxycholate in rats. Liver 13:262-269, 1993
5. Azer SA, Stacey NH: Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid. Hepatology 18:311A. 1993 (abstract)
6. Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR: Tauroursodeoxycholate increases rat liver ursodeoxycholate levels and limits lithocholale formation better than ursodeoxycholate. Gastroenterology 109:564-572, 1995
7. Armstrong MJ, Carey MC: The hydrophobic/hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res 23:70-80, 1982
8. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L: Bile acid-induced liver toxicity: Relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 19:57-69, 1986
9. Hofmann AF, Popper H: Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2:398-399, 1987
10. Heuman DM: Quantitative estimation of the hydrophobic-hydrophilic balance of mixed bile salt solutions. J Lipid Res 30:719-730, 1989
11. Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1:834-836, 1987
12. Leuschner U. Fischer H, Kurtz W, et al: Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial. Gastroenterology 97:1268-1274, 1989
13. Battezzati PM, Podda M, Bianchi FB, et al: Ursodeoxycholic acid for symptomatic primary biliary cirrhosis: Preliminary analysis of a double-blind multicentre trial. J Hepatol 17:332-338, 1993
14. Chazouillères O, Poupon R, Capron JP, et al: Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 11:120-123, 1990
15. Beuers U, Spengler U, Kruis W, et al: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology 16:707-714, 1992
16. Colombo C, Setchell KDR, Podda M, et al: Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 117:482-489, 1990
17. Poupon RE, Balkau B, Eschwège E, Poupon R, UDCA-PBC Study Group: A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 325:1548-1554, 1991
18. Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OFW: A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 9:162-168, 1994
19. Heathcote EJL, Cauch-Dudek K, Walker V, et al: The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19:1149-1156, 1994
20. Lindor KD, Dickson ER, Baldus WP, et al: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106:1284-1290, 1994
21. Combes B, Carithers RL Jr, Maddrey WC, et al: A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22:759-766, 1995
22. Poupon RE, Poupon R, Balkau B, UDCA-PBC Study Group: Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 330:1342-1347, 1994
23. Batta AK, Salen G, Shefer S, Tint GS, Dayal B: The effect of tauroursodeoxycholic acid and taurine supplementation on biliary bile acid composition. Hepatology 2:811-816, 1982
24. Taal BG, Schalm SW, ten Kate FWJ, Hermans J, Geertzen RGM, Feltkamp BEW: Clinical diagnosis of primary biliary cirrhosis: A classification based on major and minor criteria. Hepatogastroenterology 30:178-182, 1983
25. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York, McGraw-Hill, 1971, pp 220-228
26. Vonk RJ, Kneepkens CMF, Havinga R, Kuipers F, Bijleveld CMA: Enterohepatic circulation in man: A simple method for the determination of duodenal bile acids. J Lipid Res 27:901-904, 1986
27. Rossi SS, Converse JL, Hofmann AF: High-pressure liquid chromatographic analysis of conjugated bile acids in human bile: Simultaneous resolution of sulphated and unsulphated lithocholyl amidates and the common conjugated bile acids. J Lipid Res 28:589-595, 1987
28. Setchell KDR, Worthington J: A rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse phase octadecylsilane bonded silica cartridge. Clin Chim Acta 125:135-144, 1982
29. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York, McGraw-Hill, 1971, pp 514-603
30. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York, McGraw-Hill, 1971, pp 196-201
31. Street JM, Setchell KDR: Chromatographic methods for bile acid analysis. Biomed Chromatogr 2:229-241, 1988
32. Setchell KDR, Rodrigues C, Podda M, Crosignani A: Metabolism of tauroursodeoxycholic acid given by mouth in patients with primary biliary cirrhosis. Gut 1996 (in press)
33. Podda M, Ghezzi C, Battezzati PM, et al: Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 34:595-65S, 1989
34. Crosignani A, Podda M, Battezzati PM, et al: Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 14:1000-1007, 1991
35. Walker S, Stiehl A, Raedsch R, Kloters P, Kommerell B: Absorption of urso- and chenodeoxycholic acid and their taurine and glycine conjugates in rat jejunum, ileum, and colon. Digestion 32:47-52, 1985
36. Ota M, Minami Y, Hoshita T: Intestinal absorption of ursodeoxycholic, glycoursodeoxycholic and tauroursodeoxycholic acids in rats. J Pharmacobio-Dyn 8:114-118, 1985
37. Poupon R, Chrétien Y, Parquet M, Ballet F, Rey C, Infante R: Hepatic transport of bile acids in the isolated perfused rat liver. Structure-kinetic relationship. Biochem Pharmacol 37:209-212, 1988
38. Aldini R, Roda A, Simioni P, Lenzi P, Roda E: Uptake of bile acids by perfused rat liver: Evidence of structure-activity relationship. Hepatology 10:840-845, 1989
39. Jazrawi RP, de Caestecker JS, Goggin PM, et al: Kinetics of hepatic bile acids handling in cholestatic liver disease: Effect of ursodeoxycholic acid. Gastroenterology 106:134-142, 1994
40. Poupon RE, Ouguerram K, Chrétien Y, et al: Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 17:577-582, 1993
41. Bachrach WH, Hofmann AF: Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part I. Dig Dis Sci 27:737-761, 1982
42. Bachrach WH, Hofmann AF: Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II. Dig Dis Sci 27:833-856, 1982
43. Ponz de Leon M, Carulli N, Loria P, Ioria R, Zironi F: Cholesterol absorption during bile acid feeding. Effect of ursodeoxycholic acid (UDCA) administration. Gastroenterology 78:214-219, 1980
44. Roda A, Grigolo B, Pellicciari R, Natalini B: Structure-activity relationship studies on natural and synthetic bile acid analogs. Dig Dis Sci 34:24S-35S, 1989
45. Hofmann AF: Chemistry and enterohepatic circulation of bile acids. Hepatology 4:4S-14S, 1984
46. Hofmann AF, Roda A: Physicochemical properties of bile acids and their relationship to biological properties: An over-view of the problem. J Lipid Res 25:1477-1489, 1984